Recognizing that radioligand therapy is most effective early when tumors are "target-rich," new clinical trials accelerate dosing and intensity upfront. This strategy aims to deliver the most significant therapeutic blow before diminishing returns set in as the tumor responds and the target is lost.

Beyond efficacy, new therapies like bispecifics require significant institutional support. Clinicians need training for unfamiliar side effects like CRS, and facilities need resources like observation units and admission protocols, creating a steep implementation curve for clinical practice.

After years of successfully intensifying hormonal therapy, the focus in prostate cancer is shifting toward de-intensification. Researchers are exploring intermittent therapy for top responders and developing non-hormonal approaches like radioligands to spare patients the chronic, life-altering side effects of permanent castration.

Early neoadjuvant trials in the 1990s failed to show clinical benefit because they included many low-risk patients and used less potent hormonal therapies. The PROTEUS trial's success was built on learning from this history by strictly enrolling high-risk patients and using a powerful androgen receptor pathway inhibitor (ARPI).

The rapid advancement of ARPIs wasn't just a scientific breakthrough. It was a rare convergence of FDA interest in new endpoints, a deeper biological understanding of castration resistance, and intense industry and academic collaboration that created a uniquely fertile ground for innovation.

Johnson & Johnson's data for its drug Erlita doesn't just offer an incremental improvement; it challenges the century-old practice of immediate radical prostatectomy for high-risk prostate cancer. Integrating pharmaceutical treatment before and after surgery could fundamentally shift the treatment paradigm from a purely surgical approach to a multidisciplinary one.

Progress in prostate cancer was historically challenged because trials in the 80s-2000s included a large proportion of patients with low-risk disease (e.g., Gleason 6). These patients didn't require aggressive therapy, which "contaminated" results and made it difficult to discern the true benefit of new treatments for high-risk populations.

A major trial on a less-frequent dosing schedule for denosumab in patients with bone metastases is being presented in a breast cancer session because it included both patient populations. This highlights the need for oncologists to monitor key research outside their specialty, as practice-changing data can emerge from unexpected places.

Three 2025 trials (AMPLITUDE, PSMA-addition, CAPItello) introduced personalized therapy for metastatic hormone-sensitive prostate cancer. However, significant benefits were confined to narrow subgroups, like BRCA-mutated patients. This suggests future success depends on even more stringent patient selection, not broader application of targeted agents.